Work Here?
Overview
Opella produces over-the-counter medicines, vitamins, minerals and supplements for a global audience, with about 100 brands and 11,000 employees. Its products are ready-to-use self-care remedies sold without prescription, covering needs like pain relief, digestion and allergy relief. The company differentiates itself through a large global manufacturing footprint (13 sites) and dedicated science and innovation centers, plus its status as a certified B Corp focused on health for people and the planet. Its goal is to simplify self-care, putting health in people’s hands for half a billion consumers and growing its trusted portfolio through manufacturing excellence and science-backed development.
About Opella
Industries
Healthcare
Consumer Goods
Company Size
5,001-10,000
Company Stage
N/A
Total Funding
N/A
Headquarters
Neuilly-sur-Seine, France
Founded
2018
Get referred to Opella
See people who can refer or advise you
Simplify's Take
What believers are saying
- July 2026 Mexico line adds 200 million mini-bottles, lifting local manufacture to 80%.
- March 2026 FIP partnership strengthens pharmacist influence and supports self-care adoption.
- February 2026 Australia electrification funding cuts gas use and lowers operating emissions.
What critics are saying
- Americans reach shelves only in 2027-2028, delaying Mexico expansion payback and execution.
- Opella still relies on Sanofi-era shared branding, while ownership remains split with CD&R.
- Any Enterogermina validation failure at Ocoyoacoyoc freezes Americas supply and damages flagship probiotic sales.
What makes Opella unique
- April 30, 2025: CD&R and Sanofi made Opella an independent consumer-health leader.
- Opella owns 100 brands, 11,000 employees, and 13 manufacturing sites globally.
- July 2026: Mexico makes Enterogermina API and finished product, a rare capability.
Help us improve and share your feedback! Did you find this helpful?
Benefits
Hybrid Work Options
Growth & Insights and Company News
6 month growth
↑ 75%1 year growth
↑ 75%2 year growth
↑ 26%Karan Bhatia joins Asahi Group as director-agps. Karan Bhatia has transitioned from Sanofi and Opella to join Asahi Group as Director-AGPS. Announcing the move on LinkedIn, he reflected on closing a nine-year chapter with the two organisations, expressing gratitude for the experiences and opportunities gained during his tenure. Karan Bhatia has embarked on a new professional journey, joining Asahi Group as Director-AGPS after nearly a decade with Sanofi and its subsidiary Opella. The development was shared by Bhatia in a LinkedIn update, where he confirmed his departure from the pharmaceutical giant and expressed appreciation for the formative years he spent across the two organisations. "Last week, I closed a professional chapter of nine years with Sanofi & Opella. I'm grateful for my time in these two world-class organisations," he wrote, signalling both the end of a significant tenure and the beginning of a fresh chapter with Asahi Group. Bhatia's move marks a notable shift from the healthcare and pharmaceutical sector to the global beverage industry, underscoring the breadth of his professional expertise and adaptability. Sanofi, a multinational pharmaceutical company headquartered in Paris, and Opella, its consumer healthcare arm, provided him with a platform to contribute to diverse markets and complex business environments. His nine-year association with the two companies reflects a period of sustained growth and leadership, during which he played a role in advancing business strategies and operational excellence. The transition to Asahi Group, a leading Japanese beverage and food company with a strong international footprint, positions Bhatia within a dynamic sector known for innovation and global consumer engagement. As Director-AGPS, he is expected to bring his extensive experience in corporate leadership, strategic planning and cross-sectoral collaboration to strengthen Asahi's global operations. Industry observers note that such cross-sectoral moves are increasingly common among senior executives, reflecting the convergence of skills required across industries. Bhatia's background in healthcare and pharmaceuticals equips him with a unique perspective on consumer needs, regulatory frameworks and international business practices, which are highly relevant to the fast-evolving beverage industry. His announcement has drawn attention within professional circles, with peers and colleagues acknowledging his contributions to Sanofi and Opella while extending best wishes for his new role. The move also highlights the growing trend of leaders leveraging their expertise across diverse industries to drive transformation and growth. For Asahi Group, the appointment underscores its commitment to strengthening leadership capabilities and enhancing its global strategy. For Bhatia, it represents both continuity and change: continuity in his pursuit of impactful leadership, and change in embracing new challenges within a different sector. Discover more from creative brands mag. Brand Management Discover more advertising Business Operations Missing Persons & Abductions July 30, 2026 Discover more Shopping Portals
The Week in Health: Hospital investment, Cyclospora Outbreak. By Sergio Arturo Lievano Madrigal | Journalist - Fri, 07/24/2026 - 09:59 DIA assistant Mexico's health sector moved on two fronts this week: public infrastructure spending and private manufacturing investment both accelerated, while a cross-border food safety scare tested coordination with the FDA. Meanwhile, a cholesterol drug approval and an insurtech's growth rounded out a week defined by expanding access to care. Ready? This is the Week in Health! Mexico Unveils MX$181 Billion Hospital Infrastructure Plan The government will invest close to MX$181 billion through 2030 to build, expand, or replace 152 public hospitals, growing the IMSS, ISSSTE, and IMSS Bienestar network past 106,000 beds. The plan responds to long-documented funding disparities across Mexico's fragmented public health subsystems. Mexico Modernizes Public Hospitals as Medical Device Market Grows ISSSTE's MX$298 million investment in electric beds and operating room upgrades coincides with LINET Group's new Santa Fe headquarters, signaling sustained demand for medical equipment. Together, the moves point to a multi-front procurement cycle spanning commodity and specialized devices alike. Mexico Investigates Cyclospora Outbreak Mexican authorities activated a joint task force with the FDA to investigate a cyclospora outbreak linked to lettuce from Guanajuato-based supplier Taylor Farms. The case carries real stakes for Mexico's vegetable export sector, which sends nearly 96% of its output to the United States. FDA Approves Merck Oral Pill for High Cholesterol The US FDA approved Lipfendra, Merck's first-in-class oral PCSK9 inhibitor, aimed at the 70% of statin patients who still miss their cholesterol targets. The approval carries relevance for Mexico, where cardiovascular disease remains a leading cause of mortality. Opella Expands Enterogermina Production Line in State of Mexico Opella inaugurated a MX$1.2 billion production line in Ocoyoacac, part of a MX$2.3 billion plan to raise local manufacturing for the domestic market to 80%. The project positions the site as a global backup facility and is expected to create 500 direct and indirect jobs. Disrupting Mexican Healthcare Through Tech-Driven InsurTech Mutuus' Jean-Louis Brunet tells MBN the insurtech now serves 14,000 members through a zero-deductible, direct-payment model targeting Mexico's underserved middle class. He says recent IVA tax changes forced a 23% workforce cut, even as the company grows more than 40% annually.
Opella inaugurates new $70m-backed production line. Healthcare company Opella has announced that it has inaugurated a new production line for Enterogermina in Mexico following a US$70 million (c. £52m) investment. Reportedly, the highly automated facility in Ocoyoacac will add an annual capacity of 200 million mini-bottles. It will serve as a complementary regional hub to Opella's plant in Origgio, Italy, and will operate on 100% renewable electrical energy. Opella chief supply chain officer, Rafik Amrane, said: "This new production line in Mexico is a crucial step forward in its broader mission to build a highly resilient, global manufacturing network. "By increasing our production capacity and being closer to the markets we serve, we are fundamentally changing how we deliver care, ensuring that our science-backed solutions are consistently available to the millions of families who rely on them." Following rigorous qualification and regulatory approvals, the new production line will progressively scale operations to bring the product to shelves across the Americas in the 2027-2028 period. Opella Mexico general manager, Luis Soares, said: "With this new production line, Logistics Manager is strengthening Mexico's role as a strategic platform for advanced pharmaceutical manufacturing and exports to Latin America. "It will also enable us to increase the share of Opella products sold in Mexico that are locally manufactured from 60% to 80%, combining stronger, sustainable local production with greater regional reach." IntraLogisteX is taking place in Dallas in 2026, bringing the industry's leading trade show & conference to one of North America's most important logistics hubs. Reuben joined Akabo Media as assistant editor of CiTTi - one of Logistics Manager's sister publications - in October 2023. He has worked in digital and print publications since graduating in MA Publishing in 2022. He holds a great interest in transport technology and innovation. Outside of work, Reuben is also a huge football fan. 24th July 2026 21st July 2026
Opella shifts Enterogermina production to Mexico. 23 July, 2026 Opella has transferred production of its flagship probiotic Enterogermina from Italy to Mexico, marking a major milestone in the company's manufacturing strategy for the Americas. The move is supported by a US$70 million investment in a new production line at its Ocoyoacac facility in the State of Mexico, part of a broader US$135 million expansion plan running through 2028. The expansion transforms the Ocoyoacac plant into the company's second global manufacturing hub for Enterogermina, complementing its long-established facility in Origgio, Italy. For the first time, the Mexican site will produce both the active pharmaceutical ingredient and the finished product, bringing advanced manufacturing capabilities that were previously concentrated in Europe. The new production line adds an annual capacity of 200 million mini-bottles, enabling Opella to meet growing demand across Latin America while strengthening the resilience of its global supply network. Company executives said producing closer to key markets will improve supply chain efficiency and support faster regional distribution. As production ramps up, the share of Opella products sold in Mexico that are manufactured locally will increase from 60% to 80%. The company also expects the facility to play a larger role as an export platform, supplying multiple Latin American markets from Mexico. Beyond expanding manufacturing capacity, the investment includes a significant transfer of industrial expertise and production technology. According to the company, the project equips the Mexican operation with specialized know-how and quality systems required to manufacture one of the world's leading probiotic brands under the same standards applied in Europe. The Ocoyoacac facility also supports Opella's sustainability objectives. The site operates with 100% renewable electricity, has significantly reduced carbon emissions over the past several years, and follows a zero-waste-to-landfill model, aligning manufacturing expansion with the company's environmental commitments. With the relocation of Enterogermina production, Mexico assumes a more strategic role within Opella's global manufacturing network, reinforcing the country's position as an emerging pharmaceutical production and export hub for the Americas.
Opella appoints Radu Stănescu as Country Head Romania & Moldova. Published on July 23, 2026 Opella, the consumer healthcare company with the third-largest portfolio in the Over the Counter (OTC) and Vitamins, Minerals & Supplements (VMS) market globally, announces the appointment of Radu Stănescu as Country Head for Romania & Moldova. Radu Stănescu brings extensive commercial leadership experience from multinational organizations, including Beiersdorf and Reckitt. Radu Stănescu, Country Head for Romania & Moldova at Opella: "Together with our team, I look forward to building on the strong foundations already in place, serving consumers across Romania and Moldova through our loved brands and working closely with healthcare professionals to empower people to choose health and self-care brands with confidence." In Romania and Moldova, Opella serves consumers with a broad portfolio of health and self-care solutions, including OTC medicines as well as food supplement brands such as Enterogermina and MagneVie. Post Views: 14,698 The first Cobra II tactical armoured vehicles built entirely in Mediaș left the factory... July 24, 2026 PPC Group's entry into the Hungarian energy market, one of Europe's fastest-growing clean energy... July 24, 2026 TeraPlast Group inaugurated its TeraPlast Iberia polyethylene pipe factory in Spain, an important step... July 24, 2026 Rețele Electrice România, part of the PPC group in Romania, has completed the modernization... July 24, 2026 The first Cobra II tactical armoured vehicles built entirely in Mediaș left the factory... July 24, 2026 PPC Group's entry into the Hungarian energy market, one of Europe's fastest-growing clean energy... July 24, 2026 TeraPlast Group inaugurated its TeraPlast Iberia polyethylene pipe factory in Spain, an important step... July 24, 2026
Opella is Hiring for 159 Jobs on Simplify!
Find jobs on Simplify and start your career today
About Opella
Industries
Healthcare
Consumer Goods
Company Size
5,001-10,000
Company Stage
N/A
Total Funding
N/A
Headquarters
Neuilly-sur-Seine, France
Founded
2018
Opella is Hiring for 159 Jobs on Simplify!
Find jobs on Simplify and start your career today